Liver Cancer Clinical Trials
Before a new liver cancer treatment is introduced, clinical trials are performed to see how the treatment compares to current options. For instance, researchers may compare a new chemotherapy drug to a drug that is commonly prescribed for liver cancer, helping to determine if the new medication can more effectively treat the condition or reduce the number of side effects that patients experience.
The clinical trials process is important not only for introducing new treatment options, but also for determining how to use those options most effectively. For instance, trials may study how a specific treatment affects people with different types and stages of liver cancer, allowing oncologists to more successfully individualize each patient’s treatment in the future.
Where are clinical trials performed?
Not all cancer centers offer clinical trials. Moffitt Cancer Center, however, has been actively involved in liver cancer research for several decades. We are the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida – a designation that recognizes our longstanding commitment to scientific leadership.
At Moffitt, our clinical trials have produced many significant advances in liver cancer treatment. We have studied a variety of biologic therapies, surgical techniques, chemotherapy drugs and radiation delivery methods that have directly improved patient outcomes. In many cases, these advances have become the "gold standard" for liver cancer treatment in all settings – but our patients were able to access them first.
To learn more about our liver cancer clinical trials, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online. Our clinical trial navigators can help you explore our current trials and determine if any are right for your specific needs. You do not need a physician’s referral to seek treatment at Moffitt.
-
Clinical Trials
CLINICAL TRIAL 21923
A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants with Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Condition: Gastrointestinal Tumor
Intervention: Atezolizumab (Tecentriq); Avastin (Bevacizumab); Bevacizumab (); Pembrolizumab (Keytruda); TTI-101 ()
CLINICAL TRIAL 22002
A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in RAS
Condition: Multiple
Intervention: RMC-6236 ()
CLINICAL TRIAL 22363
Development and Implementation of a Standardized 3D-Printing Application to Optimize Routine Individualized Patient-Specific Surgical Care of Hepatobiliary Tumors
Condition: Gastrointestinal Tumor
Intervention:
CLINICAL TRIAL 22685
Phase 1/1B, Multicenter, Open-Label, Study of RMC-9805 in Participants with Advanced KRASG12D-Mutant Solid Tumors
Condition: Multiple
Intervention: RMC-6236 (); RMC-9805 ()
CLINICAL TRIAL 23065
A Phase 2, Open-label, Multicenter Study Investigating RP2 Oncolytic Immunotherapy in Combination with Second-line Therapy in Patients with Locally Advanced Unresectable, Recurrent and/or Metastatic Hepatocellular Carcinoma
Condition: Gastrointestinal Tumor
Intervention: AMP-514 (Durvalumab); Atezolizumab (Tecentriq); Avastin (Bevacizumab); Bevacizumab (); Durvalumab (); MEDI4736 (Durvalumab); RP2 ()
CLINICAL TRIAL 23188
A Phase II Study of Enfortumab Vedotin in Patients with Advanced or Metastatic Colorectal Cancer or Hepatocellular Carcinoma
Condition: Gastrointestinal Tumor
Intervention: Enfortumab Vedotin (Padcev)
CLINICAL TRIAL 23480
A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations
Condition: Multiple
Intervention: CGT4859 ()
CLINICAL TRIAL 23536
A Phase I/II Open-Label Study to Evaluate the Safety, Cellular Kinetics and Efficacy of AZD5851, a Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against GPC3 in Adult Participants With Advanced/Recurrent Hepatocellular Carcinoma: ATHENA
Condition: Gastrointestinal Tumor
Intervention: AZD5851 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
CLINICAL TRIAL 23589
A Phase 1, Open-Label Study of ABSK-011 to Assess Safety, Tolerability, and Pharmacokinetics in Patients with Advanced Solid Tumors
Condition: Gastrointestinal Tumor
Intervention: ABSK-011 ()